Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 8;48(1):168.
doi: 10.1186/s13052-022-01361-z.

Drug dosing in children with obesity: a narrative updated review

Affiliations
Review

Drug dosing in children with obesity: a narrative updated review

Francesca Gaeta et al. Ital J Pediatr. .

Abstract

Childhood obesity and its associated comorbidities are highly prevalent diseases that may add to any other possible health problem commonly affecting the pediatric age. Uncertainties may arise concerning drug dosing when children with obesity need pharmacologic therapies. In general, in pediatric practice, there is a tendency to adapt drug doses to a child's total body weight. However, this method does not consider the pharmacological impact that a specific drug can have under a two-fold point of view, that is, across various age and size groups as well. Moreover, there is a need for a therapeutic approach, as much as possible tailored considering relevant interacting aspects, such as modification in metabolomic profile, drug pharmacokinetics and pharmacodynamics. Taking into account the peculiar differences between children with overweight/obesity and those who are normal weight, the drug dosage in the case of obesity, cannot be empirically determined solely by the per kg criterion. In this narrative review, we examine the pros and cons of several drug dosing methods used when dealing with children who are affected also by obesity, focusing on specific aspects of some of the drugs most frequently prescribed in real-world practice by general pediatricians and pediatric subspecialists.

Keywords: Children; Clinical practice, pharmacodynamics, pharmacokinetics, therapy, pharmacology; Drug dosing; Drugs; Obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. WHO. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 2 Sep 2022.
    1. Kyler KE, Wagner J, Hosey-Cojocari C, Watt K, Shakhnovich V. Drug dose selection in pediatric obesity: available information for the Most commonly prescribed drugs to children. Paediatr Drugs. 2019;21(5):357–369. doi: 10.1007/s40272-019-00352-8. - DOI - PMC - PubMed
    1. StorcksdieckGenanntBonsmann S, Wills JM. Nutrition labeling to prevent obesity: reviewing the evidence from Europe. CurrObes Rep. 2012;1(3):134–140. doi: 10.1007/s13679-012-0020-0. - DOI - PMC - PubMed
    1. Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92(2):251–265. doi: 10.1016/j.mayocp.2016.09.017. - DOI - PubMed
    1. Ameer B, Weintraub MA. Dosing common medications in hospitalized pediatric patients with obesity: a review. Obesity (Silver Spring) 2020;28(6):1013–1022. doi: 10.1002/oby.22739. - DOI - PubMed